Xerese

Xerese is a brand name of acyclovir/hydrocortisone topical, approved by the FDA in the following formulation(s):

XERESE (acyclovir; hydrocortisone - cream; topical)

• 
  Manufacturer: VALEANT INTL
  
  Approval date: July 31, 2009
  
  Strength(s): 5%;1% ^[RLD]

Has a generic version of Xerese been approved?

No. There is currently no therapeutically equivalent version of Xerese available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xerese. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Nucleoside analogs in combination therapy of herpes simplex infections
  Patent 6,514,980
  Issued: February 4, 2003
  Inventor(s): Malcolm Richard; Boyd
  Assignee(s): Novartis International Pharmaceutical Ltd.
  A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or penciclorivir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections.
  
  Patent expiration dates:
  
  
  • January 24, 2017
    
    ✓ 
    Patent use: NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
    ✓ 
    Drug product
  
  



• 
  Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester
  Patent 7,223,387
  Issued: May 29, 2007
  Inventor(s): Lekare; Gunilla
  Assignee(s): Medivir AB
  A topical composition comprising an antiinflammatory glucocorticoid and a nucleoside analogue antiviral agent in a pharmaceutical carrier characterized in that the carrier comprises about 15 to about 25 weight % propylene glycol and about 10 to about 25 weight percent isopropyl C12–C22 alkanoic ester. The compositions have utility in the treatment or prophylaxis of herpesvirus infections and exhibit superior antiviral and therapeutic efficacy and an improved shelf life.
  
  Patent expiration dates:
  
  
  • February 28, 2021
    
    ✓ 
    Patent use: NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical combination
  Patent RE39264
  Issued: September 5, 2006
  Inventor(s): Harmenberg; Johan & Kristofferson; Ann Harriet Margareta
  Assignee(s): Medivir AB
  The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the prophylactic and curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of a combination of a topically acceptable antiviral substance and an antiinflammatory glucocorticoid for the manufacture of a medicament for said prophylactic and curative treatment.
  
  Patent expiration dates:
  
  
  • February 2, 2016
    
    ✓ 
    Patent use: NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 31, 2012 - NEW COMBINATION
  
  

See also...

• Xerese Cream Consumer Information (Wolters Kluwer)
• Xerese Consumer Information (Cerner Multum)
• Xerese Advanced Consumer Information (Micromedex)
• Acyclovir/Hydrocortisone Cream Consumer Information (Wolters Kluwer)
• Acyclovir and hydrocortisone topical Consumer Information (Cerner Multum)
• Acyclovir and hydrocortisone Topical application Advanced Consumer Information (Micromedex)